Reviewed: MR in pulmonary hypertension and RV failure

Pulmonary hypertension (PH) is characterized by pulmonary vascular remodelling, leading to progressive increase in pulmonary artery pressure and subsequent right ventricular failure. Aldosterone and the mineralocorticoid receptor (MR) are key drivers of cardiovascular disease and MR antagonists are well-established in more…

Endothelial cell mineralocorticoid receptors drive pulmonary hypertension and RV failure

Mineralocorticoid receptor (MR) antagonists are well established in the treatment of chronic left heart disease, however, there is an ever growing body of evidence suggesting potential benefits in other cardiovascular disease. Here, we evaluated the effects of MR antagonists on more…

Call for Papers: Emerging fields for therapeutic targeting of the aldosterone-mineralocorticoid receptor signaling pathway

The British Journal of Pharmacology will be publishing a special ‘Themed Issue’ entitled “Emerging fields for therapeutic targeting of the aldosterone-mineralocorticoid receptor signaling pathway” with Achim Lother, Ulrich Wenzel and Frédéric Jaisser as Guest Editors. Call for papers: https://bpspubs.onlinelibrary.wiley.com/hub/journal/14765381/aldosterone-mineralocorticoid.html